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ABSTRACT 
The mitochondria theory of aging proposes that accumulation of mitochondrial DNA 
(mtDNA) with pathogenic mutations, and the resultant respiration defects, are responsible 
not only for mitochondrial diseases but also for aging and age-associated disorders, 
including tumor development. This theory is partly supported by results obtained from our 
transmitochondrial mice (mito-mice), which harbor mtDNA with mutations that are 
orthologous to those found in patients with mitochondrial diseases: mito-mice express 
disease phenotypes only when they express respiration defects caused by accumulation of 
mutated mtDNA. With regard to tumor development, specific mtDNA mutations that 
induce reactive oxygen species (ROS) enhance malignant transformation of lung carcinoma 
cells to cells with high metastatic potential. However, age-associated respiration defects in 
elderly human fibroblasts are due not to mtDNA mutations but to epigenetic regulation of 
nuclear-coded genes, as indicated by the fact that normal respiratory function is restored by 
reprogramming of elderly fibroblasts.  
 
Introduction 
Because mitochondria are highly oxygenic organelles that produce ROS and because many 
chemical carcinogens have been shown to accumulate in mitochondria, mtDNA in 
mitochondria experiences stress of both endogenous ROS and exogenous chemical 
carcinogens. Therefore, the mitochondria theory of aging holds that mtDNA accumulates 
mutations much faster than does nuclear DNA, and the resultant respiration defects are 
responsible for the expression of mitochondrial diseases, aging, and age-associated 
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disorders [1–6]. For example, the three most prevalent mitochondrial diseases (chronic 
progressive external ophthalmoplegia [CPEO]); myoclonic epilepsy with ragged-red fibers 
[MERRF]; and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like 
episodes [MELAS]) are believed to be caused by mtDNA harboring a large-scale deletion 
(ΔmtDNA), a single point mutation in the tRNALys gene, and a single point mutation in the 
tRNALeu(UUR) gene, respectively [1–3]. Moreover, in addition to their associations with 
mitochondrial diseases, these mtDNA mutations are hypothesized to be associated with 
human aging and age-associated disorders, including oncogenic transformation of normal 
cells to develop tumors. However, no convincing evidence for this hypothesis has yet been 
discovered. 
 
Mito-mice as models for mitochondrial diseases and for gene therapy 
Mitochondrial diseases that show maternal inheritance are considered to be due to mtDNA 
with pathogenic mutations that induce respiration defects upon their accumulation [1–3]. 
However, we cannot exclude the possible involvement of nuclear abnormalities in the 
pathogenesis of these diseases. To confirm that mtDNA mutations are responsible for these 
diseases, we have to generate transmitochondrial mice (mito-mice) harbouring mtDNA 
with large-scale deletions (ΔmtDNA) or point mutations that are orthologous to those found 
in patients with mitochondrial diseases. These mice are effective for precise investigation 
of disease pathogenesis and for development of effective gene therapies for these diseases.  
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In previous studies [7, 8], we generated mito-miceΔ, which harbor ΔmtDNA and therefore 
are disease models for CPEO, by transferring ΔmtDNA from a mouse cell line into the 
germline of female B6 mice. In addition, we recently generated new mito-mice that harbor 
mtDNA with a pathogenic G7731A mutation in the tRNALys gene (mito-mice-tRNALys7731), 
which may be useful as models for MERRF [9]. These mito-mice share the B6 nuclear 
background and express disease phenotypes only when respiration defects are induced by 
accumulation of mtDNA with pathogenic mutations [7–9], suggesting that the mtDNA 
mutations are responsible for respiration defects and the resultant expression of 
abnormalities (Fig. 1). 
Mito-miceΔ have also been used for development of gene therapy in embryos [10] and in 
adult mice [11]. Because inheritance of mammalian mtDNA is strictly maternal (from 
mother to children) [12], maternal transmission of mitochondrial diseases to progeny has 
been effectively prevented by the use of nuclear transplantation into enucleated zygotes of 
normal mice [10]. In adult mice, bone marrow transplantation from normal mice to mito-
miceΔ has been shown to be effective for partial prevention of the expression of disease 
phenotypes [11]. 
Subsequently, human embryos are used to perform nuclear transplantation from oocytes of 
one woman into enucleated oocytes from an unrelated woman for future prevention to 
transmit mitochondrial diseases [13-15]. However, there are few cases for which this 
technology is applicable. Because most children born from mothers affected by 
mitochondrial diseases, such as MERRF or MELAS, do not express disease phenotypes [16, 
17], most of the oocytes of affected mothers do not have sufficient amounts of the mutated 
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mtDNA to induce diseases, probably because oocytes with large amounts of mutated 
mtDNA are not viable. 
We recently reported an alternative therapeutic strategy that does not use oocytes from 
unrelated women and instead uses oocytes from affected mothers [9]. MERRF model mice 
(mito-mice-tRNALys7731) show stochastic segregation of the heteroplasmic mtDNA 
(mtDNA with and without the mutation), and the resultant marked variation in the 
proportions of G7731A mtDNA among pups due to bottleneck effects [18–20]. Considering 
that abnormalities are not observed in mito-mice-tRNALys7731 with low proportions of 
G7731A mtDNA [9], simple selection of oocytes with extremely low proportions of the 
mutated mtDNA from affected mothers likely would be sufficient to yield unaffected 
children (Fig. 2). 
 
Regulation of metastasis by mutations in mtDNA 
Respiration defects and the resultant upregulation of glycolysis under normoxia enable cell 
growth under hypoxia and thus are thought to be involved in tumor development [21−24]. 
Because pathogenic mtDNA mutations also induce upregulation of glycolysis under 
normoxia by inducing mitochondrial respiration defects, pathogenic mtDNA mutations or 
somatic mutations in mtDNA have been proposed to induce tumor development [1−3].  
If this proposal is correct, patients with mitochondrial diseases can be expected to 
preferentially develop tumors, because patients express upregulation of glycolysis under 
normoxia due to the pathogenic mutations in mtDNA. However, no statistical evidence for 
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association between mitochondrial diseases and tumor development in patients has been 
reported.  Moreover, if we assume that some mtDNA mutations, irrespective of whether 
they are pathogenic or polymorphic, induce tumor development, all family members 
sharing a mother carrying such mutations should develop tumors as a result of the maternal 
inheritance of mtDNA, but no bias toward maternal inheritance of tumor development has 
been reported. Nonetheless, it is still possible that mtDNA mutations are involved in 
processes other than tumor development (oncogenic transformation of normal cells into 
tumor cells); for example, mtDNA mutations may be involved in malignant transformation 
of tumor cells into highly metastatic tumor cells. 
Our previous studies [25–27] have provided convincing evidence that mtDNA with a 
pathogenic G13997A mutation in the ND6 gene (G13997A mtDNA) controls the malignant 
transformation of B6-derived lung carcinoma cells from poorly metastatic into highly 
metastatic (Fig. 1), whereas this mutation does not control tumor development 
(transformation of normal cells into tumor cells). Moreover, because the induction of high 
metastasis is due not to the respiration defects but rather to overproduction of ROS, 
expression of high metastatic potential can be reversibly controlled by treatment with 
antioxidants [25–27], indicating that antioxidant administration effectively prevents 
development of high metastatic potential in tumor cells. 
The effects of G13997A mtDNA on aging and tumor development in living mice can be 
examined by generating mito-mice-ND613997, which carry the nuclear genome from B6 
mice and G13997A mtDNA from B6-derived lung carcinoma cells [28]. Mito-mice-
ND613997 do not express premature aging phenotypes and have a normal lifespan but show 
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lactic acidosis, hyperglycemia, and lymphoma development, indicating the possible 
involvement of mtDNA mutations in lymphoma development in B6 mice (Fig. 1). However, 
considering that the B6 nuclear background is prone to lymphoma development, G13997A 
mtDNA might not develop lymphoma independently. By generating mito-mice with 
G13997A mtDNA and a nuclear background from the A/J strain mice, which are not prone 
to lymphoma development, we show that these mito-mice do not develop lymphoma [29]. 
These results indicate that G13997A mtDNA simply enhances the frequency of lymphoma 
development, which is due primarily to abnormalities in the B6 nuclear genome. 
 
Epigenetic regulation of human age-associated respiration defects  
The mitochondrial theory of aging also holds that ROS overproduction and the resultant 
accumulation of somatic mutations in mtDNA are responsible for aging and age-associated 
respiration defects [1–6]. This contention is supported partially by subsequent studies [30, 
31], which have generated mtDNA mutator mice expressing a proofreading-deficient 
mtDNA polymerase: mtDNA mutator mice show accelerated accumulation of somatic 
mutations in mtDNA due to the proofreading deficiency and the resultant expression of 
respiration defects and early-onset aging phenotypes. However, it appears controversial that 
mtDNA mutator mice do not show ROS overproduction [31], and mito-mice-ND613997 
overproducing ROS do not show early-onset aging phenotypes [28]. Moreover, one 
important question that has to be addressed is whether elderly human subjects really 
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accumulate such amounts of somatic mtDNA mutations as the mtDNA mutator mice do in 
their tissues. 
Our previous studies have suggested the involvement of nuclear mutations in the age-
associated respiration defects found in elderly human fibroblasts, as indicated by 
experiments involving mtDNA transfer from elderly fibroblasts into mtDNA-less HeLa 
cells [32] and by experiments involving nuclear DNA transfer from mtDNA-less HeLa 
cells into elderly fibroblasts [33]. Because transfer of the nuclear genome from mtDNA-
less HeLa cells (that is, the nuclear genome uncontaminated by mtDNA) into elderly 
fibroblasts restores the respiration defects, these defects must be caused not by mtDNA 
mutations but by nuclear-recessive mutations [33]. However, our findings can also be 
explained by assuming the involvement of epigenetic regulation of nuclear genes in the 
absence of nuclear-recessive mutations.  
The issue of whether age-associated respiration defects observed in elderly human subjects 
are due to mutations or to epigenetic changes is resolved by reprogramming of human 
fibroblasts [34]. First, we show that age-associated mitochondrial respiration defects are 
expressed in the absence of either ROS overproduction in the mitochondria or the 
accumulation of somatic mutations in mtDNA indicating that these aging phenotypes 
expressed in human fibroblasts are not caused by mtDNA mutations [34]. Moreover, when 
elderly fibroblasts are reprogrammed by the creation of induced pluripotent stem cells 
(iPSCs), reduced respiratory function is restored, suggesting that epigenetic—not genetic—
regulation confers these human aging phenotypes [34]. It is therefore likely that these age-
associated respiration defects are controlled neither by ROS overproduction nor by 
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mutations but rather by reversible epigenetic regulation of nuclear genes (Figs. 1 and 3). A 
recent study [35] proposes that reprogramming also recovers other aging phenotypes of 
human fibroblasts, such as abnormal mitochondrial metabolism, shortened telomeres, and 
limited proliferation capacities. Therefore, most age-related phenotypes in human 
fibroblasts are under epigenetic regulation. 
The question then arises as to which nuclear genes cause age-associated mitochondrial 
respiration defects by means of epigenetic regulation? A microarray analysis has revealed 
that epigenetic downregulation of nuclear-coded genes, including GCAT and SHMT2, 
which regulate glycine production in mitochondria, results in respiration defects [34]. 
Given that the age-associated respiration defects in elderly fibroblasts are likely due in part 
to reduced translation activity in the mitochondria [32, 33], defects in glycine metabolism 
in the mitochondria as a result of a reduction in SHMT2 and GCAT expression would be 
partly responsible for the reduction in mitochondrial translation, resulting in the expression 
of age-associated respiration defects. For generalization of the concept that age-related 
phenotypes in human fibroblasts are under epigenetic regulation, further works are 
necessary to show whether epigenetic regulation of aging phenotypes are common to other 
human tissues.  
Our major arguments are summarized in Fig. 1. 
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Fig. 1. Mutations in mtDNA regulate mitochondrial diseases and tumor phenotypes but do not 
regulate age-associated respiration defects 
 
 
 
 
Fig. 2. Two strategies, nuclear transplantation and oocyte selection, for primary prevention of 
maternal inheritance of mitochondrial diseases 
 
Fig. 3. Reversible regulation of age-associated respiration defects observed in fibroblasts from 
elderly human subjects 
 
 
